TYK-00540 is a novel oral small-molecule inhibitor that simultaneously targets cyclin-dependent kinases 2, 4, and 6 (CDK2/4/6), key enzymes regulating cell cycle progression and tumor cell proliferation. By blocking these kinases, TYK-00540 aims to overcome resistance mechanisms seen with existing CDK4/6 inhibitors and more effectively disrupt cancer cell growth.

This open-label, multi-center Phase Ib/II clinical trial evaluates the safety and preliminary antitumor activity of TYK-00540 in combination with enzalutamide, an androgen receptor inhibitor, in patients with mCRPC who have previously failed novel endocrine therapies. The study includes a dose-escalation phase to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs), followed by an expansion phase to assess efficacy signals at the recommended doses.

Initial data from this study will provide important information on the tolerability of combined CDK2/4/6 inhibition and androgen receptor blockade, potentially offering a new therapeutic option for advanced prostate cancer resistant to standard hormonal treatments. The dual targeting of cell cycle progression and androgen signaling pathways reflects a rational strategy to address tumor growth driven by multiple mechanisms.

Clinical trial.